Related Experiment Video

Updated: Jun 22, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity

Jennifer Dourlat1, Wang-Qing Liu, Florence Sancier

  • 1Université Paris Descartes, UFR Biomédicale, France.

Biochimie
|May 28, 2009
PubMed

Insights

Researchers explored STAT3 (Signal Transducer and Activator of Transcription 3) inhibitors for cancer therapy. A phosphotyrosyl peptide disrupted STAT3 dimerization, impacting cancer cell proliferation and gene expression, revealing new therapeutic strategies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor crucial for tumorigenesis.
  • STAT3 dimerization, mediated by SH2 domain interactions, is a key target for cancer therapies.
  • Developing small molecule inhibitors of STAT3 dimerization is a promising therapeutic strategy.

Purpose of the Study:

  • To evaluate a phosphotyrosyl peptide ligand (P1) for its ability to inhibit STAT3 dimerization and biological activity.
  • To investigate the anti-cancer effects of a vectorized form of P1 (P1a) in STAT3-dependent cancer cells.
  • To identify novel STAT3 inhibitors based on peptide structures.

Main Methods:

  • Combinatorial chemistry was used to design a phosphotyrosyl peptide ligand (P1).
  • In vitro assays measured the inhibition of STAT3 dimerization by P1 (IC50 = 9 microM).
  • Cell-based assays assessed the biological activity of vectorized P1a in STAT3-dependent cancer cells, analyzing cell proliferation and gene expression.

Main Results:

  • The phosphotyrosyl peptide P1 effectively inhibited STAT3 dimerization with a K(d) of 0.34 microM.
  • Vectorized P1a demonstrated interaction with STAT3 in cells, significantly affecting cell proliferation.
  • P1a modulated the expression of STAT3-controlled cell cycle and apoptosis regulators.
  • A non-phosphorylated vectorized peptide (P2a) was unexpectedly identified as a potent STAT3 inhibitor.

Conclusions:

  • Peptidomimetics targeting the STAT3 SH2 domain are effective inhibitors of STAT3 dimerization and function.
  • STAT3 inhibition via P1a offers a potential therapeutic approach for STAT3-dependent cancers.
  • The discovery of P2a broadens the scope for developing novel STAT3-targeting cancer drugs.

More Related Videos

Protein Purification-free Method of Binding Affinity Determination by Microscale Thermophoresis10:22

Protein Purification-free Method of Binding Affinity Determination by Microscale Thermophoresis

Published on: August 15, 2013

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...